Stock listing
ANNX Stock Price, News, Filings & Events — Annexon, Inc.
Selected listing: ANNX · BOATS · USD · US
This page tracks Annexon, Inc.'s ANNX:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ANNX:BOATS. ANNX:BOATS is the stock-level entry point for investors researching Annexon, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Annexon, Inc. is a public company traded under the ticker ANNX in the American market. The company has a market capitalization of approximately $855.26 million. Annexon focuses on developing therapies for neurodegenerative diseases and other serious conditions.
- Ticker
- ANNX:BOATS
- Asset type
- Stock
- Market cap
- $942.2M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- BOATS
- Currency
- USD
Annexon, Inc. ANNX:BOATS stock context
This page tracks Annexon, Inc.'s ANNX:BOATS listing on BOATS in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ANNX:BOATS. ANNX:BOATS is the stock-level entry point for investors researching Annexon, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Annexon, Inc. is a public company traded under the ticker ANNX in the American market. The company has a market capitalization of approximately $855.26 million. Annexon focuses on developing therapies for neurodegenerative diseases and other serious conditions.
Latest news from Annexon, Inc.
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
August 12, 2026
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 ...
August 12, 2026
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
August 10, 2026
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
July 30, 2026
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patie...
July 14, 2026
Annexon, Inc. earnings calls
Research Annexon, Inc.
Annexon, Inc. investor report
Review AI stock analysis and investor report context for ANNX:BOATS.
Annexon, Inc. company profile
View the public company page for Annexon, Inc. on 6ix.
Annexon, Inc. news
Read company news and market updates connected to Annexon, Inc..
Annexon, Inc. investor events
Find investor webinars, events, and replay context for Annexon, Inc..